Mabwell Bioscience

688062 · SSE STAR Market

Public Market Listing

688062SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Mabwell Bioscience are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
B7-H3Antibody–drug conjugate
Non-Small Cell Lung Cancer
MW02No recent activity
Phase 2/3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Phase 2
IL-33/ST2 · ST2 (IL1RL1)Monoclonal antibody
Chronic Obstructive Pulmonary Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
9MW1911Phase 2Chronic Obstructive Pulmonary Disease COPD
Est. primary completion 2027-12 · NCT07292714 · CT.gov ↗
What to watch
7MW3711Phase 1/2Solid Tumor
Est. primary completion 2027-12-31 · NCT07466160 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
7MW3711Phase 3Lung Squamous Cell Carcinoma
Est. primary completion 2029-03 · NCT07831863 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 December 2025Topline result9MW1911Phase IIa study in COPD completed: exacerbation rates reduced versus placebo
CN · Mabwell · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$18M$24M—$35Mreport ↗